Lipocine — Third Quarter 2026 Earnings Summary

Lipocine Inc. reported a net loss of $0.7 million for the third quarter of 2026, a significant improvement from the $3.2 million loss in the same period of 2025. Total revenue for the quarter reached $2.3 million, driven by $2.1 million in license and collaboration revenue alongside $190,000 in royalty revenue from TLANDO sales. The company's unrestricted cash, cash equivalents, and marketable investment securities increased to $21.5 million as of September 30, 2026. Recent corporate updates include the initiation of the Phase 3 BLOOM study for LPCN 1154 to treat postpartum depression and regulatory approvals for TLANDO in Canada and the UAE.